Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is a safe and effective treatment for severe alopecia areata.

The best treatment for lichen planopilaris is a combination of clobetasol, hydroxychloroquine, and N-acetylcysteine.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Tofacitinib may help treat Lichen Planopilaris, but more research is needed.

Cedrol may be an effective treatment for colorectal cancer.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Omalizumab is generally safe for chronic urticaria, but hair loss is a common side effect.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

A three-year-old girl survived a rare serious infection caused by BCG vaccination, which improved after treatment with a leprosy drug.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Switching to generic tacrolimus was safe, effective, and saved money.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

Oral steroids may effectively treat recurrent intussusception in children with ILH, possibly avoiding surgery.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Pharmacists play a crucial role in patient care and education.

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Tenofovir is more effective than adefovir for resistant hepatitis B, Fibroscan is good for assessing liver damage, regulatory T cells may help hepatitis C persist, and other insights into liver health and disease were found.

Early diagnosis and treatment are crucial for managing Berardinelli–Seip syndrome.

Small bowel lesions in Cronkhite-Canada syndrome persist despite steroid treatment.

Baricitinib may help people with long-term alopecia areata.

Leuprolide plus estrogen is more effective than oral contraceptives for reducing hirsutism.